Bioharvest Sciences (BHST) Cash & Equivalents (2023 - 2025)

Bioharvest Sciences' Cash & Equivalents history runs 3 years deep, the most recent figure standing at $23.0 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents rose 863.39% year-over-year to $23.0 million in Q4 2025; TTM through Dec 2025 was $23.0 million, a 863.39% increase from a year earlier, with the FY2025 full-year figure at $23.0 million, up 863.39% from the prior year.
• Cash & Equivalents grew to $23.0 million in Q4 2025 per BHST's latest filing, from $11.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $23.0 million in Q4 2025 and bottomed at $2.4 million in Q1 2024.
• The 3-year median for Cash & Equivalents is $3.7 million (2025), against an average of $6.6 million.
• Across the five-year window, Cash & Equivalents slumped 55.37% in 2024 and surged 863.39% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $5.4 million in 2023, then slumped by 55.37% to $2.4 million in 2024, then jumped by 863.39% to $23.0 million in 2025.
• Per Business Quant, the three latest BHST Cash & Equivalents figures stand at $23.0 million (Q4 2025), $11.0 million (Q3 2025), and $3.7 million (Q2 2025).